Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$8.58
+2.0%
$7.40
$2.18
$11.12
$92.28M0.9131,296 shs50,515 shs
Givaudan SA stock logo
GVDNY
Givaudan
$83.55
-0.2%
$86.65
$81.37
$110.32
$38.58B0.7338,285 shs8,473 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
+0.42%-6.05%-11.55%+127.53%+144.26%
Givaudan SA stock logo
GVDNY
Givaudan
-0.10%-2.20%+0.47%-14.24%-20.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$8.58
+2.0%
$7.40
$2.18
$11.12
$92.28M0.9131,296 shs50,515 shs
Givaudan SA stock logo
GVDNY
Givaudan
$83.55
-0.2%
$86.65
$81.37
$110.32
$38.58B0.7338,285 shs8,473 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
+0.42%-6.05%-11.55%+127.53%+144.26%
Givaudan SA stock logo
GVDNY
Givaudan
-0.10%-2.20%+0.47%-14.24%-20.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
0.00
N/AN/AN/A
Givaudan SA stock logo
GVDNY
Givaudan
2.50
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest GVDNY, SY1, 1COV, BNR, and CRDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/12/2025
Givaudan SA stock logo
GVDNY
Givaudan
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeModerate SellHold
7/8/2025
Givaudan SA stock logo
GVDNY
Givaudan
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$536.30M0.17N/AN/A$7.39 per share1.16
Givaudan SA stock logo
GVDNY
Givaudan
$8.42B4.58$3.56 per share23.50$11.26 per share7.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-$47.49M-$1.90N/AN/A-26.04%-23.61%-15.73%N/A
Givaudan SA stock logo
GVDNY
Givaudan
$1.24BN/A0.0027.944.97N/AN/AN/AN/A

Latest GVDNY, SY1, 1COV, BNR, and CRDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/8/2025Q2 2025
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A-$0.15N/A-$0.15N/A$20.74 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/AN/AN/AN/AN/A
Givaudan SA stock logo
GVDNY
Givaudan
$0.961.15%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A
3.22
2.97
Givaudan SA stock logo
GVDNY
Givaudan
0.86
1.49
0.98

Institutional Ownership

CompanyInstitutional Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.03%
Givaudan SA stock logo
GVDNY
Givaudan
0.01%

Insider Ownership

CompanyInsider Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.30%
Givaudan SA stock logo
GVDNY
Givaudan
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
1,39010.76 million7.50 millionNot Optionable
Givaudan SA stock logo
GVDNY
Givaudan
16,942461.68 millionN/ANot Optionable

Recent News About These Companies

Hawkins (NASDAQ:HWKN) vs. Givaudan (OTCMKTS:GVDNY) Financial Survey
Givaudan price target lowered to CHF 4,300 from CHF 4,400 at JPMorgan
Stifel Nicolaus Keeps Their Hold Rating on Givaudan SA (GIVN)
Givaudan price target lowered to CHF 4,450 from CHF 45,550 at Citi
Givaudan SA (GVDNY)
Givaudan SA Reports Strong 2024 Earnings Performance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Burning Rock Biotech stock logo

Burning Rock Biotech NASDAQ:BNR

$8.57 +0.17 (+1.96%)
As of 01:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Givaudan stock logo

Givaudan OTCMKTS:GVDNY

$83.55 -0.20 (-0.23%)
As of 01:20 PM Eastern

Givaudan SA manufactures, supplies, and sells fragrance, beauty, taste, and wellbeing products to the consumer goods industry. The company operates through divisions, Fragrance & Beauty, and Taste & Wellbeing. The Fragrance & Beauty division offers fine fragrances; consumer products, such as personal, home, fabric, and oral care; fragrance ingredients; and active beauty products. The Taste & Wellbeing division provides beverages, such as fizzy drinks, bottled waters, ready-to-drink juices, alcoholic beverages, and others; dairy and cheese products, including dairy drinks, yoghurt, ice cream, chilled desserts, cream cheese, and spreads; snacks; givaudan flavour ingredients; savory, and supplements and nutraceutical products; and biscuits, crackers, and cereals, as well as confectionery products, such as chewing gums, chocolates, and sweets. It operates in Switzerland, Europe, Africa, the Middle East, North America, Latin America, and the Asia Pacific. Givaudan SA was founded in 1796 and is headquartered in Vernier, Switzerland.